Jabil announced that it acquired Pharmaceutics International, Inc. (Pii), a CDMO specializing in pharmaceutical manufacturing. Pii offers early stage, clinical and commercial volume aseptic filling, lyophilization and oral solid dose manufacturing. Jabil completed the acquisition on Feb. 3. “As the pace of healthcare innovation accelerates, pharmaceutical companies need partners who can help them scale rapidly…
Uniphar expands global pharma manufacturing footprint in U.S., Ireland, The Netherlands
Uniphar announced today that it launched three new state-of-the-art facilities to expand its international presence. The company unveiled new facilities in Raleigh, North Carolina, Lelystad, The Netherlands, and Dublin, Ireland. It says the facilities mark its commitment to enhancing logistics and distribution capabilities within the global pharmaceutical and healthcare sectors. Uniphar said the locations position…
GE HealthCare invests $138M in Ireland contrast media manufacturing plant
GE HealthCare (Nasdaq: GEHC) announced a $138 million investment to expand its contrast media fill/finish manufacturing site in Cork, Ireland. The company plans to expand with a new, state-of-the-art facility on the existing grounds of the Carrigtohill, Cork, site. It anticipates 25 million more patient doses per year of contrast media by the end of…
Nelipak earns certifications at Derry facility
Nelipak announced today that it received International Sustainability and Carbon Certification (ISCC) Plus for its Derry, Northern Ireland facility. ISCC PLUS is a globally recognized standard tracking recycled and bio-based materials through the supply chain. It verifies that companies meet environmental and social standards. Cranston, Rhode Island-based Nelipak manufactures healthcare packaging solutions and offers complementary…
Aragen brings in $100M to expand pharma outsourcing offerings
Aragen announced that it received a $100 million investment to support the expansion of its pharmaceutical outsourcing services. Quadria Capital, an Asian healthcare-focused private equity fund, made the investment. This results in the company acquiring a minority stake in Aragen, primarily through a fresh capital infusion. A small portion comes from the sale of shares…
WuXi to sell Irish vaccine site to Merck ahead of potential U.S. law limiting Chinese biotech business
Merck agreed to acquire a vaccine manufacturing facility in Ireland from WuXi, the Irish Foreign Direct Investment Arm (IDA) announced today. IDA Ireland said the move comes as part of long-term plans in Ireland for Merck Sharp & Dohme (MSD), Rahway, New Jersey–based Merck’s Ireland business. The acquisition of the facility, located in Dundalk, brings…
PharmaEssentia commits to interferon therapy production amid shortage
PharmaEssentia has reaffirmed its commitment to creating access to critical interferon therapies amid a reported global shortage. The Burlington, Massachusetts-based company noted a recent reported shortage of Pegasys (peginterferon alfa-2a), a treatment for hepatitis C and B. With concerns growing over drug shortages for other therapies, the company said its established cGMP manufacturing network and…
African Union vaccine initiative receives $45M
An African Union effort to strengthen public health and improve vaccine access in Africa has received a $45 million financing package. The U.S. International Development Finance Corporation, the African Development Bank and the International Finance Corporation (IFC) jointly announced the package for VaxSen, a subsidiary of Senegal’s Institut Pasteur de Dakar (IPD). This agreement underscores…
Lilly gets nod to market locally manufactured insulin in Egypt
Eli Lilly (NYSE:LLY) announced today that the Egyptian Drug Authority approved insulin glargine manufactured in partnership with Eva Pharma. The companies launched their collaboration in 2022 to deliver a sustainable supply of high-quality, affordable human and analog insulin. It wants to bring insulin to at least 1 million people annually living with diabetes in low- to…
Novo Nordisk invests $1.2B in Denmark production plant
Novo Nordisk announced today that it plans to invest $1.2 billion (8.5 billion Danish kroner) in a new production facility in Odense, Denmark. The company said this marks the first time in this century that it breaks ground in Denmark by establishing a new production site. Novo Nordisk plans to include a state-of-the-art finished production…